1 Start 2 Complete InstructionsPlease complete the Module 5: Lipid Management Follow-up Survey and tell us what you learned from this module. Your response is important, and will be used to demonstrate the value of this educational program and to guide development of future CME activities. Thank you for your participation. Please provide your email so we can contact you with promotional information including drawings and prizes for completing this survey. This field is optional. When “LDL’ is measured as part of a routine metabolic panel, it includes which of the following lipoproteins: * Only LDL Both large, buoyant and small dense LDL but no other lipoproteins LDL, intermediate density lipoproteins (which contain remnants of the triglyceride-rich lipoproteins), and Lp(a) Lipoproteins that only containing apolipoprotein B (apoB) Which of the following statements about Lp(a) is Not True: * Lp(a) is an LDL-like particle to which apo(a) is attached by disulfide linkage Can be associated with an increased risk of aortic stenosis Levels in an individual subject are largely determined by genetic factors Can be modified by diet and exercise Is often the sole identifiable risk factor for premature cardiovascular disease What is the DIRECT mechanism of action of inclisiran? * Acts as an antibody against PCSK9 Decreases PCSK9 levels by inhibiting the translation of PCSK9 Prevents the binding of PCSK9 to the LDL receptors Decreases the amount of LDL receptors According to the 2018 AHA/ACC cholesterol guidelines, coronary artery calcium (CAC) assessment is recommended in patients: * With intermediate/borderline/unclear risk Very high-risk patients (primary prevention setting) Very high-risk patients (secondary prevention setting) Unsure A 42-year-old male patient with type 2 diabetes mellitus has an LDL-C of 110 mg/dL and has a family history of ASCVD. He is not currently on any lipid-lowering therapy. What would you recommend for LDL-C reduction? * Further risk assessment and medical history to determine if he should be on a statin CAC score to determine if he should be on a statin No risk assessment needed, initiate moderate intensity-statins Add statin and a PCSK9 inhibitor How many patient encounters have you had in the last 90 days? * <200 200 400 600 800 1000 1200 >1200 As a result of this educational activity, did you make any changes to your clinical practice? * Yes No What specific changes did you make to your practice as a result of information received in this activity? (Select all that apply) * Assess LDL-C and other markers of residual risk, including TG and Lp(a) to guide ASCVD prevention and lipid-lowering therapy Intensify lipid-lowering therapy early and effectively, utilizing the full spectrum of statin and non-stain therapies to prevent ASCVD events Consider comprehensive methods, including imaging, biomarkers, and genetics/family risk when calculating ASCVD risk What additional improvements have you made in your clinical practice after participating in this activity? * What barriers are currently preventing you from making these changes? (select all that apply) * Formulary restrictions Insurance/financial issues Time constraints Lack of interprofessional team support System constraints Treatment related adverse events Patient adherence/compliance None Were the changes that you made in clinical practice beneficial to patient care?* * Yes No Has this course improved the comprehensive treatment of your patients with cardiometabolic disease or cardiometabolic risk? * Yes No Please explain your above answer. * Leave this field blank
